pathogen
reduct
elimin
reduc
risk
nucleic
acid
contain
agent
includ
bacteria
thu
effect
prion
diseas
possibl
introduc
pr
platelet
plasma
concentr
resourc
develop
pr
red
cell
requir
intellectu
financi
commit
nation
institut
health
food
drug
administr
industri
blood
bank
establish
occur
nucleic
acid
test
nat
technolog
done
suffici
c
publish
elsevi
inc
n
wake
human
immunodefici
viru
hiv
tragedi
food
drug
administr
fda
us
blood
establish
endors
precautionari
principl
state
situat
scientif
uncertainti
possibl
risk
taken
account
absenc
proof
contrari
corollari
precautionari
principl
assert
measur
need
taken
face
potenti
seriou
risk
yet
pathogen
reduct
pr
perhap
quintessenti
exampl
precautionari
principl
embrac
pathogen
reduct
call
new
paradigm
transfus
safeti
name
transit
reactiv
proactiv
preemptiv
strategi
prevent
transfusiontransmit
diseas
pathogen
reduct
may
initi
add
cost
complex
blood
process
ultim
offer
maximum
safeti
also
prove
costneutr
possibl
costsav
declin
transfusionassoci
hepat
incid
near
zero
cours
decad
consid
one
major
triumph
transfus
medicin
howev
view
present
context
also
seen
one
major
failur
transfus
medicin
preemptiv
viral
reduct
strategi
place
decad
pass
extent
hepat
risk
defin
caus
agent
discov
proper
test
strategi
implement
vast
number
case
occur
could
chose
anyth
base
prospect
determin
hepat
incid
rate
number
blood
transfus
nationwid
unit
state
estim
million
transfusiontransmit
hepat
c
viru
hcv
infect
base
incid
sever
outcom
might
result
case
cirrhosi
clearli
case
cirrhosi
occur
mani
transfus
recipi
die
underli
diseas
sever
chronic
manifest
hepat
could
ensu
diminish
fact
allogen
transfus
place
recipi
potenti
risk
fatal
diseas
project
sober
even
factor
histor
long
interv
first
recognit
diseas
transfusiontransmit
eventu
implement
donorscreen
test
prevent
transmiss
tabl
hepat
b
viru
hbv
interv
recognit
transfusiontransmiss
implement
first
assay
hbv
australia
antigen
approxim
year
nona
nonb
hcv
hepat
year
hiv
interv
reduc
year
howev
compar
brief
interv
transfusiontransmit
predominantli
fatal
hiv
infect
occur
unit
state
alon
gener
consid
interv
recognit
implement
west
nile
viru
wnv
howev
retrospect
analysi
wnv
epidem
new
york
citi
made
highli
probabl
wnv
could
transmit
transfus
true
implement
interv
approxim
year
addit
test
donat
trypanosoma
cruzi
chaga
diseas
recommend
fda
blood
product
advisori
committe
yet
first
reliabl
test
introduc
furthermor
rel
frequent
transmiss
bacteria
room
temperaturestor
platelet
evid
year
later
routin
bacteriolog
test
platelet
introduc
unit
state
inher
problem
reactiv
strategi
pathogen
risk
fundament
inevit
delay
recognit
risk
prevent
risk
thu
transfusiontransmit
infect
destin
occur
adequ
react
perhap
william
murphi
phrase
best
state
effect
new
poorli
understood
diseas
long
preclin
phase
spread
among
human
transfus
mani
year
perhap
extens
consequ
becom
appar
fix
inevit
properti
transfus
medicin
nonetheless
posit
note
base
prospect
determin
hepat
incid
figur
introduct
antihcv
screen
project
prevent
million
case
transfusionassoci
hepat
potenti
case
cirrhosi
decad
furthermor
increasingli
sensit
serolog
nucleic
acid
test
hcv
hiv
reduc
risk
dramat
unit
state
risk
major
transfusiontransmit
virus
million
hcv
million
hiv
hbv
calcul
incid
ratewindow
period
model
approxim
use
minipool
nucleic
acid
test
nat
yield
model
canada
obrien
et
al
use
incid
ratewindow
period
model
report
residu
risk
million
hcv
million
hiv
hbv
although
hbv
transmiss
occur
much
frequent
hcv
hiv
estim
base
antibodi
hepat
b
core
antigen
antihbc
seroconvers
develop
hepat
b
surfac
antigen
hbsag
carrier
state
clinic
diseas
actual
case
transfusionassoci
hepat
b
quit
rare
current
major
infecti
risk
zoonot
origin
wherein
anim
virus
introduc
human
incident
host
either
food
chain
variant
creutzfeldtjakob
diseas
vector
transmiss
mosquito
tick
insect
vector
howev
evid
indirect
wnv
epidem
known
intermitt
natur
definit
action
taken
time
overal
sinc
document
transfusionassoci
case
clinic
wnv
infect
project
transmiss
unit
state
remark
none
case
would
occur
pr
system
place
time
evidenc
absenc
case
associ
transfus
solventdetergenttr
plasma
implement
wnv
test
donor
blood
highli
effect
american
red
cross
experi
wnv
nat
prevent
releas
transfus
least
potenti
infecti
compon
confirm
posit
blood
donor
wnv
transmiss
sinc
test
implement
repres
window
period
donat
fail
detect
minipool
test
format
use
current
concern
wnv
stori
may
replay
dengu
fever
viru
dfv
agent
predispos
element
similar
global
dfv
caus
million
case
dengu
fever
case
dengu
hemorrhag
fever
death
annual
transmit
aed
mosquito
found
countri
rapidli
expand
distribut
could
easili
follow
path
wnv
north
america
dfv
median
viremia
day
case
asymptomat
rna
level
rang
copi
per
millilit
thu
dengu
characterist
transfusiontransmit
agent
vector
alreadi
present
north
america
thu
far
transfusiontransmit
case
transplantrel
case
nosocomi
dengu
transmiss
document
undoubtedli
mani
transfusionassoci
dengu
case
occur
endem
area
mask
high
background
infect
rate
fortun
epidemiolog
pattern
agent
differ
wnv
intermediari
bird
host
would
facilit
spread
agent
particular
current
interest
human
herpesviru
hhv
import
potenti
transmit
kaposi
sarcoma
ks
also
critic
decis
regard
donor
reentri
men
sex
men
msm
preval
antibodi
blood
donor
gener
popul
hivneg
msm
hivposit
msm
patient
ks
dollard
sc
person
commun
sever
case
report
epidemiolog
insight
suggest
transfusiontransmit
best
data
indic
transfusiontransmiss
studi
hladik
associ
center
diseas
control
prevent
follow
transfus
recipi
endem
area
uganda
risk
seroconvers
significantli
higher
among
recipi
seroposit
blood
excess
risk
p
b
increas
seen
primarili
seroconvert
week
posttransfus
interv
highli
suggest
transfusiontransmiss
final
analysi
agent
even
transient
travers
human
circul
asymptomat
phase
infect
threat
transfusiontransmit
likelihood
transmiss
highli
depend
durat
viremia
agentemia
level
concern
depend
upon
sever
ensu
diseas
agent
routin
screen
vast
array
potenti
microbiolog
threat
requir
continu
surveil
clinic
assess
magnitud
identifi
risk
possibl
test
strategi
limit
risk
clinic
signific
agent
thu
agent
agent
process
ineffici
insensit
often
controversi
decis
inevit
appli
clinic
diseas
occur
reactiv
strategi
requir
demonstr
risk
prevent
measur
implement
encompass
effici
intuit
appeal
option
preemptiv
approach
includ
pr
almost
aforement
agent
mani
other
reduc
nonpathogen
level
nucleic
acid
intercal
agent
psoralen
riboflavin
presenc
uva
light
shown
tabl
known
log
reduct
psoralen
uva
much
could
shown
riboflavinuva
pathogen
reduct
multipl
proven
advantag
effect
inactiv
clinic
relev
virus
whether
rna
dna
singlestrand
doublestrand
envelop
nonenvelop
intracellular
extracellular
inactiv
clinic
relev
gramposit
gramneg
bacteria
inactiv
spirochet
rickettsia
protozoa
known
transfus
relev
inactiv
lymphocyt
thu
prevent
transfusionassoci
graftversushost
diseas
gvhd
offer
probabl
preemptiv
protect
pathogen
potenti
lethal
agent
inevit
emerg
futur
also
impedi
implement
pr
point
limit
widespread
applic
follow
decreas
product
yield
platelet
rang
insuffici
kill
hightit
nonenvelop
agent
hepat
viru
hav
parvoviru
howev
antibodi
agent
common
recipi
popul
document
transmiss
exceedingli
rare
concern
potenti
toxic
although
none
known
riboflavin
toxic
psoralen
theoret
low
residu
dose
transfus
agent
appear
wide
safeti
margin
significantli
present
singl
pr
system
appli
blood
product
particularli
proven
system
pr
whole
blood
pack
red
cell
anticip
high
cost
although
method
pr
red
blood
cell
rbc
proven
effect
safe
appropri
clinic
trial
evolv
technolog
establish
efficaci
multicompon
pr
implement
mani
potenti
save
would
offset
cost
process
includ
reduc
elimin
futur
need
addit
donor
screen
assay
test
babesia
ehrlichia
dengu
malaria
elimin
current
assay
includ
antihbc
wnv
cruzi
chaga
syphili
elimin
bacteri
test
platelet
discontinu
irradi
blood
product
discontinu
leukoreduct
allow
continu
minipool
test
rather
probabl
evolut
individu
donor
test
reduc
donor
exclus
base
geographi
malaria
cumul
measur
could
result
vast
save
offset
implement
cost
pr
howev
save
realiz
procedur
pr
rbc
product
fulli
oper
perhap
key
immedi
issu
efficaci
pr
evid
substanti
even
safeti
toxic
remain
theoret
rather
whether
introduc
pr
reduct
platelet
singledonor
plasma
system
place
inactiv
pathogen
rbc
product
difficult
conundrum
opinion
issu
sharpli
divid
howev
known
mani
patient
receiv
repeat
oftendaili
platelet
transfus
intermitt
accompani
rbc
transfus
also
mani
center
pool
platelet
product
vastli
increas
recipi
exposur
risk
also
probabl
wait
complet
pr
packag
anoth
year
elaps
licensur
implement
time
innumer
platelet
plasma
infus
continu
transmit
infect
recipi
could
easili
prevent
transfusiontransmiss
infect
accompani
signific
diseas
transfusiontransmit
tragedi
could
ensu
believ
precautionari
principl
moral
imper
dictat
implement
even
less
perfect
admittedli
side
coin
platelet
singledonor
plasma
inactiv
absenc
rbc
inactiv
reap
financi
offset
complet
pr
system
rbc
product
continu
transmit
diseas
furthermor
known
transfusiontransmit
pathogen
one
part
risk
equat
even
largest
part
howev
would
counter
prevent
human
error
control
transfusionrel
acut
lung
injuri
pr
mutual
exclus
way
reduc
transfus
risk
pursu
equal
vigor
solventdeterg
treatment
plasma
deriv
establish
principl
pr
even
singl
blood
compon
highli
benefici
establish
enorm
valu
preemptiv
pr
strategi
univers
inactiv
plasma
deriv
render
formerli
highestrisk
blood
product
safest
blood
transfus
servic
scrambl
meet
threat
wnv
reassur
plasma
manufactur
know
agent
preemptiv
cover
would
dfv
lipidencapsul
agent
threaten
blood
suppli
solvent
deterg
treatment
plasma
deriv
implement
earli
hiv
hcv
case
devast
hemophiliac
popul
could
avoid
statement
made
cast
retrospect
blame
take
lesson
histori
illustr
valu
protect
preemptiv
mechan
place
next
agent
strike
great
potenti
risk
delay
implement
pr
wait
absolut
evid
perfect
system
put
place
wait
calcul
risk
defi
precautionari
principl
chanc
possibl
new
lethal
agent
enter
blood
suppli
replay
hiv
tragedi
face
futur
gener
say
could
time
believ
time
come
act
present
technolog
psoralenuva
riboflavinuva
would
bring
level
safeti
platelet
current
exist
commerci
plasma
deriv
evid
efficaci
safeti
pr
platelet
singledonor
plasma
product
suffici
overwhelm
european
experi
psoralenuvatr
platelet
proven
practic
safeti
approach
transfusiontransmit
diseas
prevent
whether
one
concur
need
rapidli
introduc
pr
platelet
nonfraction
plasma
unit
state
canada
import
believ
crucial
messag
establish
mindset
say
pr
blood
product
laudatori
achiev
goal
need
invest
emot
intellectu
financi
make
happen
blood
bank
establish
nation
institut
health
fda
industri
make
concept
prioriti
work
concert
devot
substanti
resourc
energi
achiev
goal
viral
nucleic
acid
test
happen
pack
hotel
ballroom
dr
david
kessler
urg
blood
bank
develop
nat
routin
donor
screen
talk
rais
pathogen
inactiv
eyebrow
great
skeptic
posit
author
drove
system
gener
governmentindustri
collabor
result
remark
rapid
develop
practic
nat
assay
enorm
addit
blood
safeti
david
kessler
admonish
encourag
say
right
thing
find
way
bite
bullet
fortun
case
magic
bullet
